Skip to main content
61°
Partly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Kiromic BioPharma, Inc.
Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site
May 20, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
April 24, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
April 02, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial
March 19, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
March 01, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
February 28, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months
February 14, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer
January 29, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial
January 05, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer
December 14, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Announces Uplisting to OTCQB Market
November 16, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
OTC
Kiromic BioPharma Announces Deltacel™ Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer Center
November 09, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
OTC
Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement
October 23, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
OTC
Kiromic BioPharma Welcomes Two New Directors to its Board
July 24, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer
May 01, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Submits Investigational New Drug Application for Phase 1 Trial with Deltacel for Non-Small Cell Lung Cancer
April 03, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Announces Reverse Stock Split
March 10, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Reports Favorable Deltacel™ Preclinical Pharmacology Results
February 28, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Two Leading Independent Proxy Advisory Firms Recommend Kiromic BioPharma Stockholders Vote “FOR” All Proxy Proposals
February 23, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma CEO Issues Letter to Stockholders
February 16, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Arranges Up to $10 Million Financing
October 27, 2022
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Announces FDA Feedback from Type B Pre-IND Meeting Confirms Deltacel Development Strategy
October 06, 2022
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Appoints Leonardo Mirandola, Ph.D. as Chief Scientific Officer
July 12, 2022
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Achieves Milestone with Timely Completion of Expanded cGMP Manufacturing Facility to Support Cell Therapy Oncology Pipeline
July 07, 2022
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Pipeline to Prioritize a New Gamma Delta T-cell Product Candidate
June 21, 2022
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Significantly Expands Gamma Delta T cell Product Pipeline with New Sponsored Research Agreement
June 07, 2022
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
May 13, 2022
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Announces Company Will Directly Submit Amended IND for Procel™ to the FDA in Second Half of 2022
May 11, 2022
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Announces Availability of Company’s Current Corporate Presentation
April 11, 2022
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Highlights
April 08, 2022
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.